Cited 0 times in
Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상인 | - |
dc.contributor.author | 임재윤 | - |
dc.contributor.author | 정희철 | - |
dc.contributor.author | 조재용 | - |
dc.contributor.author | 최승호 | - |
dc.date.accessioned | 2015-04-24T17:45:40Z | - |
dc.date.available | 2015-04-24T17:45:40Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0009-3157 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/106018 | - |
dc.description.abstract | BACKGROUND: The aim of this clinical study was to evaluate the efficacy of combination chemotherapy of oxaliplatin, leucovorin and continuous-infusion 5-fluorouracil (5-FU) for advanced gastric cancer. METHODS: Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks. The primary endpoint was overall response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS) and toxicity. RESULTS: Forty-eight patients were enrolled, and 45 were evaluable for response. A total of 320 cycles of chemotherapy were administered (median 6 cycles per patient). One complete response (2.1%) and 19 partial responses (39.6%) were noted, resulting in an ORR of 41.7% (95% confidence interval, CI: 27.7-55.6%) by intent-to-treat analysis. With a median follow-up duration of 22 months, the median PFS was 5.3 (95% CI: 2.8-7.8) months and the median OS was 13.6 (95% CI: 9.3-17.9) months. There was 1 treatment-related death, and the most common grade 3/4 toxicity was neutropenia (36.1%). Three patients discontinued treatment because of serum creatinine elevation. CONCLUSION: This study reaffirms the efficacy of oxaliplatin in advanced gastric cancer, but its dose of 100 mg/m(2) remains to be reconsidered in Korean patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 200~206 | - |
dc.relation.isPartOf | CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/secondary | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage* | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage* | - |
dc.subject.MESH | Organoplatinum Compounds/adverse effects | - |
dc.subject.MESH | Organoplatinum Compounds/therapeutic use | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae Yun Lim | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Kyung Jin Oh | - |
dc.contributor.googleauthor | Seung Ho Choi | - |
dc.contributor.googleauthor | Sang In Lee | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.identifier.doi | 10.1159/000219434 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02828 | - |
dc.contributor.localId | A03398 | - |
dc.contributor.localId | A03899 | - |
dc.contributor.localId | A04102 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00519 | - |
dc.identifier.eissn | 1421-9794 | - |
dc.identifier.pmid | 19451710 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/219434 | - |
dc.subject.keyword | Combination treatment | - |
dc.subject.keyword | FOLFOX | - |
dc.subject.keyword | Gastric cancer | - |
dc.subject.keyword | Oxaliplatin | - |
dc.contributor.alternativeName | Lee, Sang In | - |
dc.contributor.alternativeName | Lim, Jae Yun | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.alternativeName | Choi, Seung Ho | - |
dc.contributor.affiliatedAuthor | Lee, Sang In | - |
dc.contributor.affiliatedAuthor | Lim, Jae Yun | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Choi, Seung Ho | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.citation.volume | 55 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 200 | - |
dc.citation.endPage | 206 | - |
dc.identifier.bibliographicCitation | CHEMOTHERAPY, Vol.55(4) : 200-206, 2009 | - |
dc.identifier.rimsid | 56975 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.